Albert Labs

Receive alerts
Unlisted (UK)
Market Cap:
52 weeks high
52 weeks low

In brief

Albert Labs is the first psychedelic company leveraging Real World Evidence Studies to enhance patient care by accelerating access to psychedelic therapy in a hospital setting for niche indications with urgent and high unmet needs.

Through a collaboration with leading academic institutions, hospital networks and existing reimbursement mechanisms; Albert Labs empowers scientists, researchers, and medical professionals to accelerate safe patient treatment whilst collecting data to protect and improve its psilocybin based medicines.

Starting with cancer-related anxiety, depression and existential crisis, Albert Labs will bring psilocybin-assisted therapy to the UK and Europe before expanding globally.


The company is working to advance its psilocybin-based drug, KRN-101, as a treatment for cancer-related anxiety